Naxitamab

Naxitamab is a monoclonal antibody biosimilar expressed in CHO cells, targeting Ganglioside GD2, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Naxitamab is a chimeric humanized monoclonal antibody targeting the GD2 antigen. GD2 antigen is expressed on the surface of tumors generated by neuroectoderm, including neuroblastoma, melanoma and osteosarcoma. By binding to the GD2 antigen on the tumor surface, naxitamab can trigger antibody-mediated cytotoxicity and activate the complement system in the immune system to achieve the effect of killing tumors.

Target	Ganglioside GD2
Clonality	Monoclonal
Reactivity	Human
Expression	Recombinant
Tested Applications	ELISA, WB, SDS-PAGE
Host	Human, Mouse
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Isotype	IgG1 Kappa
Form	Liquid
Purity	> 95%
Purification	Purified from cell culture supernatants by Protein A/G chromatography.
Storage	Store at 4 °C if the entire vial will be used within 1-2 weeks. Aliquot and store at -20 °C or -80 °C for long term storage. Avoid repeated freeze/thaw cycles.
Buffer	0.01 M PBS. pH 7.4.
CAS Number	1879925-92-4
Concentration	3.82 mg/ml
Availability	Shipped within 7-12 working days.
Note	This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use.

Research Articles on Ganglioside GD2

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue